Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dual Specific Immunotoxin for Brain Tumor Therapy

a brain tumor and immunotoxin technology, applied in the field of anti-tumor immunotoxins, can solve the problem of increasing the overall median survival by only 75 days

Inactive Publication Date: 2013-01-24
DUKE UNIV
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this has increased the overall median survival by only 75 days.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dual Specific Immunotoxin for Brain Tumor Therapy
  • Dual Specific Immunotoxin for Brain Tumor Therapy
  • Dual Specific Immunotoxin for Brain Tumor Therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Materials and Methods

[0029]Cell Lines.

[0030]Cell lines expressing EGFRwt used were the human epidermoid carcinoma cell line A431 {Merlino, 1984} and the murine Swiss 3T3 mouse fibroblast cell line EGFRwt transfectant NR6W {Batra, 1995}. Cell lines transfected to express EGFRvIII included the murine Swiss 3T3 mouse fibroblast cell line-derived transfectant NREM {Batra, 1995}. The parental murine Swiss 3T3 mouse fibroblast cell line, NR6, was used as control. All cell lines were cultured in complete zinc option-10% fetal bovine serum (FBS) (Richter's zinc option; Invitrogen, San Diego, Calif.) and passed at confluence using 0.05% Trypsin-EDTA (Invitrogen).

[0031]Disaggregation of Xenograft Tumor Samples.

[0032]Xenograft tissues from malignant glioma (D256MG, D270MG, D2159MG) obtained under sterile conditions from the Duke animal facility were prepared for cell culture in a laminar flow hood with a sterile technique. Tumor material was finely minced with scissors and added to a trypsiniz...

example 2

Cloning of the VH and VL Domain of D2C7IgG1κ

[0050]VH and VL cDNAs were isolated from the D2C7 hybridoma by a RACE method as described in “Materials and Methods.” The heavy-chain and light-chain variable domains were cloned and sequenced. The amplified VH and VL fragments were approximately 360 and 321 bp, respectively. The deduced amino acid sequences of the D2C7 VH and VL domains are shown in FIG. 1. Sequence analysis of the VH and VL amino acids, using the database of germ-line genes (http: / / www.ncbi.nlm.nih.gov / igblast / ), revealed that the sequences were derived from different germ-line V genes with a similarity of 70% to 75%.

example 3

Construction, Expression, and Purification of D2C7-(scdsFv)-PE38 KDEL Immunotoxin

[0051]The carboxyl terminus of the D2C7 VH domain was connected to the amino terminus of the VL domain by a 15-amino-acid peptide (Gly4Ser)3 linker (SEQ ID NO: 11). In order to obtain a stable IT, it is essential to ensure that during renaturation VH is positioned near VL. This was achieved by mutating a single key residue in each chain to cysteine, for the stabilizing disulfide bond to form. On the basis of predictions using molecular modeling and empirical data with other dsFv-recombinant ITs, we chose one amino acid in each chain to mutate to cysteine {Reiter, 1996}. These are residues 44 in the framework region 2 (FR2) of VH and 100 in the FR4 of VL (according to the Kabat numbering). Thus, we prepared an Fv that contains both a peptide linker and a disulfide bond generated by cysteine residues that replace Ser44 of VH and Gly100 of VL. The D2C7 (scdsFv) PCR fragment was then fused to DNA for domain...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.

Description

[0001]This application claims the benefit of provisional application Ser. No. 61 / 044,190 filed Apr. 11, 2008, the contents of which are expressly incorporated herein.TECHNICAL FIELD OF THE INVENTION[0002]This invention is related to the area of anti-tumor immunotoxins. In particular, it relates to an immunotoxin specific for two tumor-associated antigens.BACKGROUND OF THE INVENTION[0003]Gliomas are the most common primary tumors of the central nervous system (CNS) {Louis, 1995}. Glioblastoma multiforme (GBM) is the most frequent and the most malignant type of glioma. There is a much higher incidence of GBM in adults than in children. According to the Central Brain Tumor Registry of the United States statistical report, GBM accounts for about 20% of all brain tumors in the USA (CBTRUS, 1998-2002). Current treatment for patients with GBM include, surgery followed by radiation and chemotherapy. Despite intensive research the median survival for GBM patients until the early 1990s was le...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/30G01N33/53A61P35/00C07K16/46A61K39/395
CPCA61K2039/505A61K2039/545C07K16/2863C07K2317/56C07K2317/622A61K47/48561C07K2317/92C07K2319/04C07K2319/55A61K39/39558A61K47/48484C07K2317/624A61K38/00A61P35/00A61K47/6829A61K47/6849C07K14/21C07K2317/565
Inventor BIGNER, DARELLKUAN, CHIEN-TSUNPASTAN, IRA H.PEGRAM, CHARLES N.
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com